Although effective in RA, Etanercept, as other TNF-α blockers, is an immunosuppressant and is associated with a number of serious side effects (unusual cancers, infections, congestive heart failure, CNS problems, and autoimmunity) [58], thus suggesting a need for safer treatment options, one of which might be an antibody targeting CXCL13. The gene discussed is TNF; the disease is rheumatoid arthritis.